Further support of the in‐vitro and in‐vivo relevance of miR‐224 in repressing antioxidant capacity in myeloma cells will require future experiments using ROS scavengers such as catalase and superoxide dismutase in addition to glutathione assays in HMCLs and MM mouse models, with genetic manipulation of miR‐224 expression or activity, and these studies are planned. The gene discussed is CAT; the disease is plasma cell myeloma.